0001628280-24-003867.txt : 20240208 0001628280-24-003867.hdr.sgml : 20240208 20240208160737 ACCESSION NUMBER: 0001628280-24-003867 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240208 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240208 DATE AS OF CHANGE: 20240208 FILER: COMPANY DATA: COMPANY CONFORMED NAME: agilon health, inc. CENTRAL INDEX KEY: 0001831097 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 371915147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40332 FILM NUMBER: 24609058 BUSINESS ADDRESS: STREET 1: 6210 E HWY 290 STREET 2: SUITE 450 CITY: AUSTIN STATE: TX ZIP: 78723 BUSINESS PHONE: 562-256-3800 MAIL ADDRESS: STREET 1: 6210 E HWY 290 STREET 2: SUITE 450 CITY: AUSTIN STATE: TX ZIP: 78723 FORMER COMPANY: FORMER CONFORMED NAME: Agilon Health Topco, Inc. DATE OF NAME CHANGE: 20201103 8-K 1 agl-20240208.htm 8-K agl-20240208
0001831097FALSE00018310972024-02-082024-02-08

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_____________________________________________
FORM 8-K
_____________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 8, 2024
_____________________________________________
agilon health, inc.
(Exact name of Registrant as Specified in Its Charter)
_____________________________________________
Delaware001-4033237-1915147
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
6210 E Hwy 290, Suite 450
Austin, TX
78723
(Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: 562 256-3800
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
_____________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange on which registered
Common stock, par value $0.01 per shareAGLThe New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective March 1, 2024, Benjamin Kornitzer, M.D., will assume a strategic role as special advisor to agilon health and will transition from his role as chief medical officer (CMO). The company has initiated a comprehensive search process to identify a new CMO. Until a successor is named, Dr. Karthik Rao, senior medical director and vice president, network performance, will serve as interim CMO.
The full text of this news release is attached hereto as Exhibit 99.1
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
Exhibit
Number
Description
99.1
104Cover Page Interactive Data File (formatted as Inline XBRL).


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
agilon health, inc.
Date:February 8, 2024By: /s/ Denise V. Zamore
Denise V. Zamore
Executive Vice President, Chief Legal Officer & Corporate Secretary

 EX-99.1 2 agl-8kxcmox02082024xex991.htm EX-99.1 Document
image_0a.jpg
Exhibit 99.1

agilon health Announces Chief Medical Officer Transition

AUSTIN, T.X., February 8, 2024 – agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, announced today that Benjamin Kornitzer, M.D., will assume a strategic role as special advisor to the company and will transition from his role as chief medical officer (CMO) effective March 1, 2024. agilon health has initiated a comprehensive search process to identify a new CMO. Until a successor is named, Karthik Rao, M.D., senior medical director and vice president, network performance, will serve as interim CMO. Dr. Rao and agilon’s chief clinical officer (CCO), Kevin Spencer, M.D., will co-lead the company’s clinical strategy.

“I want to express our deepest appreciation to Dr. Kornitzer for his leadership and considerable contributions to advancing our clinical, research and quality strategy at agilon health over the past four years. He has built a strong team, and we are glad to have him continue as a valued advisor,” said Steve Sell, chief executive officer, agilon health. “I am pleased to have the support of Dr. Rao as our interim chief medical officer and Dr. Spencer who serves as our chief clinical officer, both of whom play invaluable roles working with our physician partners and advancing our Total Care Model.”

Dr. Rao has a decade of experience as a practicing internal medicine physician and other roles working in value-based care. Prior to joining agilon, he worked at McKinsey & Company leading a broad range of strategy and operations work across the health care value chain with particular focus on provider groups and government organizations. Dr. Rao received his B.A. from Johns Hopkins University and holds a medical degree from Johns Hopkins University School of Medicine. He completed an internal medicine and primary care residency at Massachusetts General Hospital.

Dr. Spencer has more than 25 years of experience as a former chief executive officer (CEO) of an independent primary care practice, a practicing family medicine physician operating in value-based care and a founding agilon partner. Prior to agilon, Dr. Spencer was the CEO and chairman of Premier Family Physicians, and founder and president of the Southwest Provider Accountable Care Organization (ACO). Dr. Spencer received his medical degree from the University of Texas Health Science Center at Houston and completed his residency at the Carolinas Medical Center in North Carolina.

About agilon health
agilon health is the trusted partner empowering physicians to transform health care in our communities. Through our partnerships and purpose-built platform, agilon is accelerating at scale how physician groups and health systems transition to a value-based Total Care Model for their senior patients. agilon provides the technology, people, capital, process, and access to a peer network of 2,400+ primary care physicians that allows its physician partners to maintain their independence and focus on the total health of their most vulnerable patients. Together, agilon and its physician partners are creating the healthcare system we need – one built on the value of care, not the volume of fees. The result: healthier communities and empowered doctors. agilon is a trusted partner in 30+ diverse communities and is here to help more of our nation's leading physician groups and health systems have a sustained, thriving future. For more information visit www.agilonhealth.com and connect with us on Instagram, LinkedIn, X and YouTube.


image_0a.jpg
Contacts

Investor Contact
Matthew Gillmor
VP, Investor Relations
investors@agilonhealth.com

Media Contact
David Tauchen
Senior Director, Communications
media@agilonhealth.com

Source: agilon health

###

 EX-101.SCH 3 agl-20240208.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 0000002 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 agl-20240208_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover [Abstract] Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Registrant Name Entity Registrant Name EX-101.PRE 5 agl-20240208_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 image_0a.jpg begin 644 image_0a.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document And Entity Information
Feb. 08, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Feb. 08, 2024
Entity Registrant Name agilon health, inc.
Entity File Number 001-40332
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 37-1915147
Entity Address, Address Line One 6210 E Hwy 290
Entity Address, City or Town Austin
Entity Address, State or Province TX
Entity Address, Postal Zip Code 78723
City Area Code 562
Local Phone Number 256-3800
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.01 per share
Trading Symbol AGL
Security Exchange Name NYSE
Entity Emerging Growth Company false
Entity Central Index Key 0001831097
Amendment Flag false
XML 8 R2.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover
Feb. 08, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Feb. 08, 2024
Entity Registrant Name agilon health, inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-40332
Entity Tax Identification Number 37-1915147
Entity Address, Address Line One 6210 E Hwy 290
Entity Address, Address Line Two Suite 450
Entity Address, City or Town Austin
Entity Address, State or Province TX
Entity Address, Postal Zip Code 78723
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.01 per share
Trading Symbol AGL
Security Exchange Name NYSE
Entity Emerging Growth Company false
Entity Central Index Key 0001831097
Amendment Flag false
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 23 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Document And Entity Information Sheet http://agilonhealth.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 0000002 - Document - Cover Sheet http://agilonhealth.com/role/Cover Cover Cover 2 false false All Reports Book All Reports agl-20240208.htm agl-20240208.xsd agl-20240208_lab.xml agl-20240208_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "agl-20240208.htm": { "nsprefix": "agl", "nsuri": "http://agilonhealth.com/20240208", "dts": { "inline": { "local": [ "agl-20240208.htm" ] }, "schema": { "local": [ "agl-20240208.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "agl-20240208_lab.xml" ] }, "presentationLink": { "local": [ "agl-20240208_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://agilonhealth.com/role/DocumentAndEntityInformation", "longName": "0000001 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240208.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:CityAreaCode", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240208.htm", "unique": true } }, "R2": { "role": "http://agilonhealth.com/role/Cover", "longName": "0000002 - Document - Cover", "shortName": "Cover", "isDefault": "false", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240208.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:EntityAddressAddressLine2", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "agl-20240208.htm", "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://agilonhealth.com/role/Cover", "http://agilonhealth.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://agilonhealth.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://agilonhealth.com/role/Cover", "http://agilonhealth.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://agilonhealth.com/role/Cover", "http://agilonhealth.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://agilonhealth.com/role/Cover", "http://agilonhealth.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://agilonhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://agilonhealth.com/role/Cover", "http://agilonhealth.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://agilonhealth.com/role/Cover", "http://agilonhealth.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://agilonhealth.com/role/Cover", "http://agilonhealth.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://agilonhealth.com/role/Cover", "http://agilonhealth.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://agilonhealth.com/role/Cover", "http://agilonhealth.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://agilonhealth.com/role/Cover", "http://agilonhealth.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://agilonhealth.com/role/Cover", "http://agilonhealth.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://agilonhealth.com/role/Cover", "http://agilonhealth.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://agilonhealth.com/role/Cover", "http://agilonhealth.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://agilonhealth.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://agilonhealth.com/role/Cover", "http://agilonhealth.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://agilonhealth.com/role/Cover", "http://agilonhealth.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://agilonhealth.com/role/Cover", "http://agilonhealth.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://agilonhealth.com/role/Cover", "http://agilonhealth.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://agilonhealth.com/role/Cover", "http://agilonhealth.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://agilonhealth.com/role/Cover", "http://agilonhealth.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://agilonhealth.com/role/Cover", "http://agilonhealth.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 17 0001628280-24-003867-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-24-003867-xbrl.zip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end XML 18 agl-20240208_htm.xml IDEA: XBRL DOCUMENT 0001831097 2024-02-08 2024-02-08 0001831097 false 8-K 2024-02-08 agilon health, inc. DE 001-40332 37-1915147 6210 E Hwy 290 Suite 450 Austin TX 78723 562 256-3800 false false false false Common stock, par value $0.01 per share AGL NYSE false